Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodie...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research Jg. 26; H. 5; S. 984
Hauptverfasser:	Autio, Karen A, Boni, Valentina, Humphrey, Rachel W, Naing, Aung
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.03.2020
Schlagworte:	Animals Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Immunotherapy - adverse effects Neoplasms - drug therapy Neoplasms - immunology Prodrugs - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors
ISSN:	1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!